TG Therapeutics, Inc.
TGTX
$30.63
-$1.04-3.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 161.71M | 141.15M | 120.86M | 108.19M | 83.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.71M | 141.15M | 120.86M | 108.19M | 83.88M |
| Cost of Revenue | 28.09M | 18.94M | 15.54M | 15.40M | 9.34M |
| Gross Profit | 133.62M | 122.21M | 105.32M | 92.79M | 74.54M |
| SG&A Expenses | 63.37M | 55.59M | 50.33M | 38.96M | 41.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 132.34M | 106.31M | 112.23M | 78.24M | 71.45M |
| Operating Income | 29.37M | 34.84M | 8.62M | 29.95M | 12.43M |
| Income Before Tax | 25.91M | 30.92M | 5.47M | 25.45M | 4.27M |
| Income Tax Expenses | -364.99M | 2.73M | 408.00K | 2.12M | 388.00K |
| Earnings from Continuing Operations | 390.90M | 28.19M | 5.06M | 23.33M | 3.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 390.90M | 28.19M | 5.06M | 23.33M | 3.88M |
| EBIT | 29.37M | 34.84M | 8.62M | 29.95M | 12.43M |
| EBITDA | 29.38M | 34.86M | 8.63M | 29.96M | 12.45M |
| EPS Basic | 2.69 | 0.19 | 0.03 | 0.16 | 0.03 |
| Normalized Basic EPS | 0.11 | 0.13 | 0.02 | 0.11 | 0.02 |
| EPS Diluted | 2.43 | 0.17 | 0.03 | 0.15 | 0.02 |
| Normalized Diluted EPS | 0.10 | 0.12 | 0.02 | 0.10 | 0.02 |
| Average Basic Shares Outstanding | 145.42M | 146.74M | 146.68M | 145.24M | 145.10M |
| Average Diluted Shares Outstanding | 161.00M | 162.56M | 162.77M | 160.24M | 160.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |